These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 6505358)

  • 41. Risk factors for isoniazid (NIH)-induced liver dysfunction.
    Dickinson DS; Bailey WC; Hirschowitz BI; Soong SJ; Eidus L; Hodgkin MM
    J Clin Gastroenterol; 1981 Sep; 3(3):271-9. PubMed ID: 7288121
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Dose-dependent changes in sulfamethazine kinetics in rapid and slow isoniazid acetylators.
    Olson W; Miceli J; Weber W
    Clin Pharmacol Ther; 1978 Feb; 23(2):204-11. PubMed ID: 620482
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Isoniazid liver injury: clinical spectrum, pathology, and probable pathogenesis.
    Mitchell JR; Zimmerman HJ; Ishak KG; Thorgeirsson UP; Timbrell JA; Snodgrass WR; Nelson SD
    Ann Intern Med; 1976 Feb; 84(2):181-92. PubMed ID: 766682
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of concomitant isoniazid administration on determination of acetylator phenotype by sulphadimidine.
    Zysset T; Peretti E
    Eur J Clin Pharmacol; 1986; 30(4):463-6. PubMed ID: 3743623
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Determination of the acetylator phenotype in a Northern Nigerian population.
    Fawcett IW; Gammon PT
    Tubercle; 1975 Sep; 56(3):199-201. PubMed ID: 1216338
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The hepatic toxicity of isoniazid among rapid and slow acetylators of the drug.
    Ellard GA; Mitchison DA; Girling DJ; Nunn AJ; Fox W
    Am Rev Respir Dis; 1978 Sep; 118(3):628-9. PubMed ID: 707886
    [No Abstract]   [Full Text] [Related]  

  • 47. The influence of human N-acetyltransferase genotype on the early bactericidal activity of isoniazid.
    Donald PR; Sirgel FA; Venter A; Parkin DP; Seifart HI; van de Wal BW; Werely C; van Helden PD; Maritz JS
    Clin Infect Dis; 2004 Nov; 39(10):1425-30. PubMed ID: 15546075
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Acetylation phenotype and hepatotoxicity in the treatment of tuberculosis in children.
    Martinez-Roíg A; Camí J; Llorens-Terol J; de la Torre R; Perich F
    Pediatrics; 1986 Jun; 77(6):912-5. PubMed ID: 3487069
    [TBL] [Abstract][Full Text] [Related]  

  • 49. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
    API Consensus Expert Committee
    J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Acetylator phenotype and metabolic disposition of isoniazid in Japanese patients with systemic lupus erythematosus.
    Ishizaki T; Horai Y; Koya G; Matsuyama K; Iguchi S
    Arthritis Rheum; 1981 Oct; 24(10):1245-54. PubMed ID: 7306226
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Genetic polymorphism of isoniazid acetylation in Chilean patients with tuberculosis].
    Ligueros M; Cruz Coke R; Neira S; Saavedra H; Kramer V; Prieto JC; Gelman M; Saavedra A; Nuñez A; Pescio S
    Rev Med Chil; 1989 Dec; 117(12):1339-43. PubMed ID: 2519370
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Incidence of hepatic changes in relation to the isoniazid acetylator phenotype].
    Pilheu JA; De Salvo MC; Manchinu I; de Negroni NR; Szemzo J
    Medicina (B Aires); 1980; 40(4):382-6. PubMed ID: 7207170
    [No Abstract]   [Full Text] [Related]  

  • 53. Effects of two pulmonary tuberculosis drug treatments and acetylator status on liver function in a Zimbabwean population.
    Neill P; Pringle D; Mhonda M; Kusema T; Nhachi CF
    Cent Afr J Med; 1990 Apr; 36(4):104-7. PubMed ID: 2225025
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hepatic acetylator phenotype in bladder cancer patients.
    Ladero JM; Kwok CK; Jara C; Fernandez L; Silmi AM; Tapia D; Uson AC
    Ann Clin Res; 1985; 17(3):96-9. PubMed ID: 4051447
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Significance of the acetylator phenotype and initial oral/intravenous rifampicin administration in the treatment of tuberculosis].
    Loos U; Musch E; Schwabe HK
    Pneumologie; 1990 Feb; 44 Suppl 1():488-9. PubMed ID: 2367445
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Population screening for isoniazid acetylator phenotype.
    Seifart HI; Parkin DP; Botha FJ; Donald PR; Van Der Walt BJ
    Pharmacoepidemiol Drug Saf; 2001; 10(2):127-34. PubMed ID: 11499851
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Sulfadimidine and isoniazid loading in man and laboratory rats. Pharmacokinetic and pharmacogenetic results on drug acetylation.
    Dubbels R; Kattner E; Sell-Maurer D; Schloot W
    Arzneimittelforschung; 1980; 30(9):1574-9. PubMed ID: 7193028
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Tisamide in the complex treatment of tuberculosis].
    Onishchenko VV; Sokolova GB; Koriakin VA; Shapatava MN; Iurchenko LN
    Probl Tuberk; 1990; (7):43-5. PubMed ID: 2235951
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Polymorphic acetylation of the antibacterials, sulfamethazine and dapsone, in South Indian subjects.
    Peters JH; Gordon GR; Karat AB
    Am J Trop Med Hyg; 1975 Jul; 24(4):641-8. PubMed ID: 1155699
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Acetylator phenotype among individuals with glucose 6-phosphate dehydrogenase variants.
    Jeyakumar LH; French MR
    Xenobiotica; 1986 Dec; 16(12):1129-32. PubMed ID: 3798960
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.